EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials

Christos C Zouboulis iD, Thierry Passeron, David Pariser, Magdalena B Wozniak, Xianjun Li, Lorenz Uhlmann, Iryna Lobach, Angela Llobet Martinez, Shoba Ravichandran, Ivette Alarcon, Annamaria Offidani, Maryam S Alam und 1 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae098 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Christos C Zouboulis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Fac…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lay Summary Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful boils. HS is common and affects about 0.4% of the world’s population. Treating the condition is difficult, but drugs called ‘biologics’ can help to improve the symptoms. For example, secukinumab is a biologic drug that has been shown to be effective and well-tolerated for the treatment of HS. In this analysis, we investigated whether previous treatment with biologics could affect the effectiveness and tolerability of secukinumab. This analysis included data from two identical clinical trials (called SUNSHINE and SUNRISE) that recruited adult patients with HS who had moderate-to-severe disease. In these trials, patients took secukinumab 300 mg every 2 weeks or every 4 weeks for 1 year, or a placebo for 4 months and then switched to secukinumab until 1 year. At regular intervals, the effectiveness and tolerability of secukinumab were examined and the results were compared between patients who had previously used another biologic and patients who had never used a biologic before. After 16 weeks, patients who took secukinumab had better results than the patients who took a placebo, independent of previous biologic use. Secukinumab was still effective and had improved results over 1 year of treatment in both subgroups. Regardless of whether patients had previously been taking another biologic, secukinumab was just as tolerable as placebo and there were no new safety risks. Our analysis shows that secukinumab is effective and tolerable, regardless of whether patients have previously used another biologic drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleFemaleAdultTreatment OutcomeMiddle AgedDouble-Blind MethodDrug Administration Schedule

Substanzen

Antibodies, Monoclonal, HumanizedDermatologic Agentssecukinumab

Autor:innen und Institutionen

  • Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
  • Department of Dermatology, CHU Nice.
  • INSERM U1065, C3M, Côte d'Azur University, Nice, France.
  • Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA.
  • Novartis Ireland Ltd, Dublin, Ireland.
  • Novartis Pharma Co., Ltd, Shanghai, China.

ORCID-Profile: Christos C Zouboulis

Förderung

  • Novartis Pharma AG

Zitieren

APA

Zouboulis, C. C., Passeron, T., Pariser, D., Wozniak, M. B., Li, X., Uhlmann, L., Lobach, I., Martinez, A. L., Ravichandran, S., Alarcon, I., Offidani, A., Alam, M. S., & Mendes-Bastos, P. (2024). Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae098

Vancouver

Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae098

BibTeX
@article{Zouboulis2024,
  author = {Zouboulis, Christos C and Passeron, Thierry and Pariser, David and Wozniak, Magdalena B and Li, Xianjun and Uhlmann, Lorenz and Lobach, Iryna and Martinez, Angela Llobet and Ravichandran, Shoba and Alarcon, Ivette and Offidani, Annamaria and Alam, Maryam S and Mendes-Bastos, Pedro},
  title = {Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae098}
}
Kostenlos starten →